Claims
- 1. A protein kinase inhibitor composition comprising a compound having the chemical formula:
- 2. The composition of claim 1, wherein R1 and R2 is and OH, and R3 is hydrogen.
- 3. The composition of claim 2, further comprising a physiologically acceptable carrier.
- 4. The composition of claim 1, wherein said compound is M13.
- 5-31. (Cancelled)
- 32. A method of treating a patient having a cell proliferation disorder by administering to said patient a therapeutically effective amount of a compound of the formula:
- 33-35. (Cancelled)
- 36. The method of claim 30, wherein said disorder is characterized by inappropriate activity of EGF-R.
- 37. The method of claim 31, wherein said cell proliferative disorder is a cancer.
- 38. The method of claim 37, wherein said cancer is selected from the group consisting of breast carcinomas, stomach adenocarcinomas, salivary gland adenocarcinomas, endometrial cancers, ovarian adenocarcinomas, gastric cancers, colorectal cancers, and glioblastomas.
- 39. The method of claim 38, wherein said cancer is breast cancer.
- 40-43. (Cancelled)
- 44. The composition of claim 1, wherein R1 and R3 are isopropyl and R2 is hydroxy.
- 45. The composition of claim 44, further comprising a physiologically acceptable carrier.
- 46. The composition of claim 1, wherein said compound is M24.
- 47. The method of claim 32, wherein R1 and R2 are OH and R3 is hydroxy.
- 48. The method of claim 32, further comprising a physiologically acceptable carrier.
- 49. The method of claim 32, wherein said compound is M13.
- 50. The method of claim 32, wherein R1 and R3 are isopropyl and R2 is hydroxy.
- 51. The method of claim 32, further comprising a physiologically acceptable carrier.
- 52. The method of claim 32, wherein said compound is M24.
- 53. A method of treating a patient having a cancer characterized by over-activity of HER2, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.
- 54. A method of treating a patient having a cancer characterized by inappropriate activity of EGFR, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.
RELATED APPLICATIONS
[0001] The present application is a continuation of Chen et al. entitled “METHODS AND COMPOSITIONS FOR INHIBITING CELL PROLIFERATIVE DISORDERS”, U.S. Ser. No. 08/399,967, filed Mar. 7, 1995, (Lyon & Lyon Docket No. 211/041), which is a continuation-in-part of Chen et al., entitled “METHODS AND COMPOSITIONS FOR INHIBITING CELL PROLIFERATION-DISORDERS,” U.S. Ser. No. 08/207,933, filed Mar. 7, 1994 (Lyon & Lyon Docket No. 205/016), the entire contents of which, including the drawings, are hereby incorporated into the present application by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09953933 |
Sep 2001 |
US |
Child |
10602617 |
Jun 2003 |
US |
Continuations (3)
|
Number |
Date |
Country |
Parent |
09722149 |
Nov 2000 |
US |
Child |
09953933 |
Sep 2001 |
US |
Parent |
09070318 |
Apr 1998 |
US |
Child |
09722149 |
Nov 2000 |
US |
Parent |
08399967 |
Mar 1995 |
US |
Child |
09070318 |
Apr 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08207933 |
Mar 1994 |
US |
Child |
08399967 |
Mar 1995 |
US |